Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.57 Billion KRW | -56.69% |
| 2022 | 8.26 Billion KRW | -12.58% |
| 2021 | 9.45 Billion KRW | 80.3% |
| 2020 | 5.24 Billion KRW | 20.58% |
| 2019 | 4.34 Billion KRW | 134.28% |
| 2018 | -12.68 Billion KRW | 67.65% |
| 2017 | -39.19 Billion KRW | -5692.21% |
| 2016 | -676.71 Million KRW | 89.41% |
| 2015 | -6.39 Billion KRW | 77.79% |
| 2014 | -28.76 Billion KRW | -11.94% |
| 2013 | -25.7 Billion KRW | -45.67% |
| 2012 | -17.64 Billion KRW | 2.92% |
| 2011 | -18.17 Billion KRW | -31.38% |
| 2010 | -13.83 Billion KRW | -249.91% |
| 2009 | -3.95 Billion KRW | 10.81% |
| 2008 | -4.43 Billion KRW | -388.22% |
| 2007 | -907.86 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.36 Billion KRW | -210.66% |
| 2024 Q2 | 2.82 Billion KRW | 307.23% |
| 2023 Q4 | 1.23 Billion KRW | 15.19% |
| 2023 FY | 3.57 Billion KRW | -56.69% |
| 2023 Q1 | 1.08 Billion KRW | 124.39% |
| 2023 Q2 | 575.47 Million KRW | -46.86% |
| 2023 Q3 | 1.07 Billion KRW | 86.01% |
| 2022 Q1 | 4.92 Billion KRW | 163.61% |
| 2022 Q2 | 2.23 Billion KRW | -54.69% |
| 2022 Q4 | -4.44 Billion KRW | -214.59% |
| 2022 Q3 | 3.87 Billion KRW | 73.47% |
| 2022 FY | 8.26 Billion KRW | -12.58% |
| 2021 Q1 | 1.89 Billion KRW | 176.07% |
| 2021 Q3 | 3.57 Billion KRW | 64.49% |
| 2021 Q4 | 1.87 Billion KRW | -47.69% |
| 2021 Q2 | 2.17 Billion KRW | 14.76% |
| 2021 FY | 9.45 Billion KRW | 80.3% |
| 2020 FY | 5.24 Billion KRW | 20.58% |
| 2020 Q3 | 722.7 Million KRW | -75.72% |
| 2020 Q2 | 2.97 Billion KRW | 247.43% |
| 2020 Q4 | 686.08 Million KRW | -5.07% |
| 2020 Q1 | 856.67 Million KRW | -63.64% |
| 2019 Q4 | 2.35 Billion KRW | 2397.4% |
| 2019 FY | 4.34 Billion KRW | 134.28% |
| 2019 Q1 | 965.4 Million KRW | 108.41% |
| 2019 Q2 | 1.12 Billion KRW | 16.88% |
| 2019 Q3 | -102.54 Million KRW | -109.09% |
| 2018 FY | -12.68 Billion KRW | 67.65% |
| 2018 Q3 | -271.84 Million KRW | 31.57% |
| 2018 Q2 | -397.23 Million KRW | 25.52% |
| 2018 Q1 | -533.38 Million KRW | 98.51% |
| 2018 Q4 | -11.47 Billion KRW | -4122.46% |
| 2017 FY | -39.19 Billion KRW | -5692.21% |
| 2017 Q2 | -1.56 Billion KRW | -25.13% |
| 2017 Q4 | -35.83 Billion KRW | -6348.88% |
| 2017 Q3 | -555.62 Million KRW | 64.42% |
| 2017 Q1 | -1.24 Billion KRW | -267.88% |
| 2016 Q1 | -279.68 Million KRW | 85.48% |
| 2016 Q3 | 701.92 Million KRW | 192.39% |
| 2016 FY | -676.71 Million KRW | 89.41% |
| 2016 Q2 | -759.71 Million KRW | -171.63% |
| 2016 Q4 | -339.23 Million KRW | -148.33% |
| 2015 Q2 | -1.09 Billion KRW | 44.47% |
| 2015 Q4 | -1.92 Billion KRW | -37.05% |
| 2015 FY | -6.39 Billion KRW | 77.79% |
| 2015 Q1 | -1.96 Billion KRW | 90.79% |
| 2015 Q3 | -1.4 Billion KRW | -28.79% |
| 2014 Q3 | -2 Billion KRW | 38.19% |
| 2014 FY | -28.76 Billion KRW | -11.94% |
| 2014 Q4 | -21.34 Billion KRW | -962.9% |
| 2014 Q2 | -3.24 Billion KRW | -37.24% |
| 2014 Q1 | -2.36 Billion KRW | 89.75% |
| 2013 Q2 | -2.89 Billion KRW | -97.2% |
| 2013 FY | -25.7 Billion KRW | -45.67% |
| 2013 Q4 | -23.08 Billion KRW | -1417.0% |
| 2013 Q3 | 1.75 Billion KRW | 160.54% |
| 2013 Q1 | -1.46 Billion KRW | 78.99% |
| 2012 Q2 | -3.74 Billion KRW | -0.94% |
| 2012 Q1 | -3.7 Billion KRW | 0.0% |
| 2012 FY | -17.64 Billion KRW | 2.92% |
| 2012 Q4 | -6.98 Billion KRW | -131.83% |
| 2012 Q3 | -3.01 Billion KRW | 19.43% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 FY | -18.17 Billion KRW | -31.38% |
| 2011 Q3 | -4.68 Billion KRW | -26.93% |
| 2011 Q1 | -2.23 Billion KRW | 60.47% |
| 2011 Q2 | -3.69 Billion KRW | -64.95% |
| 2010 Q2 | -2.15 Billion KRW | -40.93% |
| 2010 Q3 | -4.49 Billion KRW | -108.87% |
| 2010 Q4 | -5.66 Billion KRW | -25.95% |
| 2010 FY | -13.83 Billion KRW | -249.91% |
| 2010 Q1 | -1.52 Billion KRW | -6979.88% |
| 2009 Q1 | -860.34 Million KRW | 48.5% |
| 2009 Q2 | 259.69 Million KRW | 130.19% |
| 2009 Q3 | -3.37 Billion KRW | -1399.5% |
| 2009 Q4 | 22.19 Million KRW | 100.66% |
| 2009 FY | -3.95 Billion KRW | 10.81% |
| 2008 Q1 | -678.79 Million KRW | 10.91% |
| 2008 Q4 | -1.67 Billion KRW | 33.77% |
| 2008 Q3 | -2.52 Billion KRW | -813.17% |
| 2008 Q2 | -276.24 Million KRW | 59.3% |
| 2008 FY | -4.43 Billion KRW | -388.22% |
| 2007 Q3 | -235.07 Million KRW | -279.33% |
| 2007 Q1 | -41.98 Million KRW | 0.0% |
| 2007 Q2 | 131.08 Million KRW | 412.25% |
| 2007 FY | -907.86 Million KRW | 0.0% |
| 2007 Q4 | -761.89 Million KRW | -224.11% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 12.87 Billion KRW | 72.201% |
| Green Cross Holdings Corporation | -54.13 Billion KRW | 106.609% |
| Green Cross Holdings Corporation | -26.63 Billion KRW | 113.435% |
| Green Cross Corporation | -26.63 Billion KRW | 113.435% |
| GeneOne Life Science, Inc. | -77.76 Billion KRW | 104.601% |
| Celltrion, Inc. | 535.64 Billion KRW | 99.332% |
| Samsung Biologics Co.,Ltd. | 857.69 Billion KRW | 99.583% |
| SK bioscience Co.,Ltd. | 22.31 Billion KRW | 83.968% |
| SK Biopharmaceuticals Co., Ltd. | -32.88 Billion KRW | 110.881% |
| Prestige BioPharma Limited | -32.92 Billion KRW | 110.868% |